17-11-2021, 12:37 AM
17-11-2021, 06:40 AM
P&M also rush right?
17-11-2021, 07:06 AM
(17-11-2021, 06:40 AM)ODA TETSURO Wrote: [ -> ]P&M also rush right?
It can be said in another way, well-managed trial tests.
17-11-2021, 07:11 AM
But the fascination with the newest, shiniest options obscured some basic facts. These two particular mRNA vaccines may have been the first to get results from Phase 3 clinical trials, but that’s because of superior trial management, not secret vaccine sauce.
Even if your candidate worked amazingly well, if you weren’t testing it in the middle of a huge outbreak, you’d have to wait a very long time for the evidence to build.
Among several wonderful options, the more old-school vaccine from Novavax combines ease of manufacture with high efficacy and lower side effects. For the moment, it’s the best COVID-19 vaccine we have.
https://www.theatlantic.com/health/archi...ne/619276/
Last October, the company’s CEO, Uğur Şahin, told German interviewers that BioNTech had sought out Pfizer for help because of the scale of the clinical-trial program necessary for drug approvals. That strategic partnership, and not simply the “triumph of mRNA,” was what propelled them past the post. (Moderna had the advantage of its partnership with the National Institutes of Health.)
Consider this: The BioNTech-Pfizer first-in-human vaccine study appeared on the U.S. government’s registry of clinical trials on April 30, 2020—the same day as the first-in-human vaccine study for Novavax, which would be going it alone. In a parallel universe where Novavax had paired up with, say, Merck, this story could have come out very differently.
Even if your candidate worked amazingly well, if you weren’t testing it in the middle of a huge outbreak, you’d have to wait a very long time for the evidence to build.
Among several wonderful options, the more old-school vaccine from Novavax combines ease of manufacture with high efficacy and lower side effects. For the moment, it’s the best COVID-19 vaccine we have.
https://www.theatlantic.com/health/archi...ne/619276/
Last October, the company’s CEO, Uğur Şahin, told German interviewers that BioNTech had sought out Pfizer for help because of the scale of the clinical-trial program necessary for drug approvals. That strategic partnership, and not simply the “triumph of mRNA,” was what propelled them past the post. (Moderna had the advantage of its partnership with the National Institutes of Health.)
Consider this: The BioNTech-Pfizer first-in-human vaccine study appeared on the U.S. government’s registry of clinical trials on April 30, 2020—the same day as the first-in-human vaccine study for Novavax, which would be going it alone. In a parallel universe where Novavax had paired up with, say, Merck, this story could have come out very differently.
17-11-2021, 07:45 AM
But Slaoui, along with other Covid-19 vaccine officials, was adamant Novavax would deliver. Slaoui, the former scientific director of Covid-19 vaccine development efforts at Operation Warp Speed, confirmed his steadfast support for Novavax in an interview with POLITICO.
"The reason we selected Novavax is because it had accumulated significant experience in ... making a recombinant protein vaccine against a virus that has a lot of similarities to Covid-19 virus,” Slaoui said, referring to the company’s ongoing efforts to develop a flu vaccine. “We knew that recombinant protein was going to be less fast than the other technologies because you have to make the protein in the appropriate structure. And it's very complex to do.”
https://www.politico.com/news/2021/10/29...ine-517503
"The reason we selected Novavax is because it had accumulated significant experience in ... making a recombinant protein vaccine against a virus that has a lot of similarities to Covid-19 virus,” Slaoui said, referring to the company’s ongoing efforts to develop a flu vaccine. “We knew that recombinant protein was going to be less fast than the other technologies because you have to make the protein in the appropriate structure. And it's very complex to do.”
https://www.politico.com/news/2021/10/29...ine-517503